You are here:

Buprenorphine (Transtec®) matrix patches

Advice

Following a full submission

Buprenorphine (Transtec) patch is not recommended for use within NHS Scotland for the treatment of moderate to severe cancer pain and severe pain that does not respond to nonopioid analgesics.

No comparative data have been provided with alternative transdermal or oral opioid preparations. The case for buprenorphine patches as a cost-minimising option when compared to the other transdermal opioid preparation marketed in the UK was not demonstrated.

The licence holder has indicated their decision to resubmit.

Drug Details

Drug Name: Buprenorphine (Transtec®) matrix patches
SMC Drug ID: 116/04
Manufacturer: Napp Pharmaceuticals Ltd
Indication: Moderate to severe cancer pain and severe pain that does not respond to non-opioid analgesics
BNF Category:
Sub Category: 4.7 Analgesics
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 13 September 2004

Back